David Sperandio

David Sperandio, Ph.D., is a medicinal chemist with more than 20 years of industry experience in drug discovery. He most recently served as an Executive Director at Biomea Fusion. He has extensive experience leading cross-functional teams from hit to lead and IND filing. While at Biomea Fusion, he led the team that identified BMF-500, a potential best-in-class targeted covalent FLT-3 inhibitor for the treatment of AML. Prior to joining Biomea Fusion, Dr. Sperandio led a collaboration of R2M Pharma with Tenaya Therapeutics, which discovered novel HDAC6 inhibitors for cardiovascular diseases and was key for the clinical development of TN-301.

Dr. Sperandio started his career at Celera and focused on the structure-guided discovery of covalent reversible serine-protease inhibitors. He later moved to Gilead Sciences, where he led the chemistry team that discovered Presatorvir (GS-5806), the first small molecule RSV fusion inhibitor that demonstrated POC in men, and Alobresib (GS-5829), a novel BRD4 inhibitor for prostate cancer.

An inventor on 23 patents and author of 25 peer-reviewed publications, Dr. Sperandio obtained his doctoral degree in Organic Chemistry from the University of Zurich, Switzerland, and completed his postdoctoral research under Professor Paul Wender at Stanford University.